OCUL - Ocular Therapeutix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.4300
-0.0500 (-1.12%)
At close: 4:00PM EDT

4.4300 0.00 (0.00%)
After hours: 4:51PM EDT

Stock chart is not supported by your current browser
Previous Close4.4800
Open4.4700
Bid4.4300 x 800
Ask4.4400 x 1000
Day's Range4.3300 - 4.5655
52 Week Range2.3500 - 7.3100
Volume394,104
Avg. Volume943,601
Market Cap189.768M
Beta (3Y Monthly)2.80
PE Ratio (TTM)N/A
EPS (TTM)-1.6520
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Trade prices are not sourced from all markets
  • Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
    Zacks5 days ago

    Allergan Announces FDA Acceptance of Glaucoma Candidate NDA

    The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.

  • Business Wire12 days ago

    Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Company entered into an employment agreement that provided for the grant of an inducement award outside the Company’s 2014 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted a stock option to purchase up to 60,000 shares of Ocular Therapeutix’s common stock. The grant was approved by the Compensation Committee of Ocular Therapeutix and was made as an inducement material to Christopher White’s entering into employment with Ocular Therapeutix as its Senior Vice President, Head of Business and Corporate Development in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Business Wire12 days ago

    Ocular Therapeutix™ Announces Christopher White as Senior Vice President, Head of Business and Corporate Development

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Christopher White as Senior Vice President, Head of Business and Corporate Development. “We are thrilled to welcome Chris to the Ocular team to oversee business and corporate development,” said Antony Mattessich, President and Chief Executive Officer. Christopher White brings over 25 years of operations management, business development, partnering and strategic planning experience in the biopharmaceutical industry.

  • Business Wire14 days ago

    Ocular Therapeutix™ Announces Patricia Kitchen as Chief Operations Officer

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Patricia Kitchen as Chief Operations Officer. “We are very excited to have Patricia joining the Ocular team in this new role to oversee both the technical operations and quality teams,” said Antony Mattessich, President and Chief Executive Officer. Having worked extensively with Patricia in the past, I believe she brings the strategic and technical expertise along with the necessary leadership skills to build upon the momentum in our technical operations and quality groups.

  • Implied Volatility Surging for Ocular (OCUL) Stock Options
    Zacks15 days ago

    Implied Volatility Surging for Ocular (OCUL) Stock Options

    Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.

  • Business Wire22 days ago

    Ocular Therapeutix™ Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the commercial launch in the United States of DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular inflammation and pain following ophthalmic surgery. DEXTENZA is the first U.S. Food and Drug Administration (FDA)-approved intracanalicular insert, a drug product with a novel route of administration that enables the delivery of drug to the surface of the eye, obviating the need for a burdensome, monthly regimen of steroid eye drops. DEXTENZA originally received FDA approval in November 2018 for the treatment of ocular pain following ophthalmic surgery.

  • Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
    Zacks29 days ago

    Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza

    Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.

  • Benzingalast month

    Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More

    Benzinga examined prospects for many investor favorite stocks over the past week. U.S. stocks finished higher for a third straight week, including new highs for the Dow and the S&P 500, bolstered by mid-week signals from the Federal Reserve. While the Fed opted to hold steady on interest rates with a reiteration that the economy remains strong, it did intimate that it is open to an interest rate cut before the end of the year.

  • Benzingalast month

    FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule

    Ocular said the FDA approved its sNDA to expand the usage of Dextenza to include the treatment of ocular inflammation following ophthalmic surgery. With the approval for the additional indication, Dextenza is now approved for the treatment of both ocular inflammation and pain following ophthalmic surgery.

  • Business Wirelast month

    Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for DEXTENZA to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication. With the approval of the sNDA, DEXTENZA is now approved for the treatment of both ocular inflammation and pain following ophthalmic surgery.

  • GuruFocus.comlast month

    Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $112,400 of Shares

    President & CEO of Ocular Therapeutix Inc (NASDAQ:OCUL) Antony C. Mattessich bought 40,000 shares of OCUL on 06/06/2019 at an average price of $2.81 a share.

  • Does Market Volatility Impact Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Share Price?
    Simply Wall St.last month

    Does Market Volatility Impact Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Share Price?

    Anyone researching Ocular Therapeutix, Inc. (NASDAQ:OCUL) might want to consider the historical volatility of the...

  • Options Traders Expect Huge Moves in Ocular (OCUL) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Ocular (OCUL) Stock

    Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.

  • Business Wire2 months ago

    Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

    Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and condition

  • Business Wire2 months ago

    Ocular Therapeutix™ Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA®

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement code for DEXTENZA® (dexamethasone ophthalmic insert). “We are pleased to receive pass-through payment status and assignment of a new C-code for DEXTENZA which physicians and their practices may use for reimbursement of the product,” said Antony Mattessich, President and Chief Executive Officer. The formal receipt of the C-code facilitates the reimbursement of DEXTENZA until such time as CMS may potentially approve a J-code and such approval becomes effective.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of OCUL earnings conference call or presentation 10-May-19 12:30pm GMT

    Q1 2019 Ocular Therapeutix Inc Earnings Call

  • Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
    Zacks2 months ago

    Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint

    Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.

  • Benzinga2 months ago

    Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline

    Ocular Therapeutix Inc (NASDAQ: OCUL )'s failure to ace a late-stage study of its glaucoma treatment candidate has tempered Raymond James' optimism, although the firm is still bullish. The Analyst Dane ...

  • Chevron, Sprint,  Ocular Therapeutix, and More: Why These Stocks Are in the Spotlight
    Insider Monkey2 months ago

    Chevron, Sprint, Ocular Therapeutix, and More: Why These Stocks Are in the Spotlight

    All eyes are on the tech sector after President Trump escalated the trade war with China by putting Chinese crown jewel Huawei on a blacklist. Predictably, many tech names fell hard on the day and the market sold off. There is nevertheless other news besides the tariff battle, and we're here to cover it. Let's […]

  • Business Wire2 months ago

    Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma

    OTX-TP failed to meet primary endpoint but achieved statistically significant reduction of intraocular pressure versus placebo at eight of the nine pre-specified time points

  • Ocular Therapeutix (OCUL) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Ocular Therapeutix (OCUL) Reports Q1 Loss, Tops Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -7.14% and 10.31%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Ocular Therapeutix: 1Q Earnings Snapshot

    The Bedford, Massachusetts-based company said it had a loss of 45 cents per share. The biotechnology company posted revenue of $492,000 in the period, topping Street forecasts. Three analysts surveyed ...

  • Business Wire2 months ago

    Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update

    DEXTENZA® Commercial Launch Scheduled for Mid-Year 2019

  • Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
    Zacks3 months ago

    Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

    Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire3 months ago

    Ocular Therapeutix™ To Report First Quarter 2019 Financial Results

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2019 financial results on Friday, May 10, 2019. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the Company’s financial results and provide a general business update. The live webcast can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.